Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a strong-buy rating in a report released on Monday,Zacks reports.

Other research analysts have also issued research reports about the company. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Leerink Partners increased their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research report on Monday, August 17th. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $750.51 on Monday. The stock has a market capitalization of $77.27 billion, a P/E ratio of 18.55, a PEG ratio of 1.47 and a beta of 0.20. The business has a 50 day simple moving average of $782.91 and a two-hundred day simple moving average of $720.82. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company posted $12.81 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insiders Place Their Bets

In related news, Director Huda Zoghbi sold 800 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,146 shares of company stock valued at $3,432,488 over the last 90 days. Company insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $11,358,000. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $5,682,636,000. Contravisory Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $6,327,000. Oxbow Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $3,342,000. Finally, Deutsche Bank AG purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $323,249,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sell-side analysts collectively rate Regeneron a “Moderate Buy,” indicating that the broader analyst consensus remains favorable. Regeneron also compares attractively on valuation against some biotechnology peers. Regeneron Pharmaceuticals Stock Rated Moderate Buy by Sell-Side Analysts
• Positive Sentiment: Biohaven has begun enrolling patients in a combination study pairing its investigational cancer therapy BHV-1530 with Regeneron’s Libtayo. The agreement could support additional development opportunities for Libtayo, though the program remains early stage. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results on October 30. The upcoming earnings release may provide updates on Eylea demand, guidance and the company’s broader pipeline, making it a near-term catalyst. Should You Buy Regeneron Pharmaceuticals Stock Before October 30?
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK results for two potential wet age-related macular degeneration treatments. The candidates met primary endpoints versus Eylea and may offer dosing approximately every six months, compared with Eylea’s current roughly eight-week schedule. The data raise the prospect of longer-term competitive pressure on Regeneron’s key eye-care franchise and prompted a sharp rally in Kodiak shares. Kodiak Skyrockets on Positive Study Data for Two Eye Drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “Sector Perform” rating and set a $737 price target, below the referenced share price, signaling limited near-term upside in that analyst’s view. Regeneron Sector Perform Rating Reaffirmed by RBC

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.